Oseltamivir phosphate(CAS NO.:204255-11-8)
Basic information
Product Name: Oseltamivir phosphate
Synonyms:
CAS: 204255-11-8
MF: C16H31N2O8P
MW: 410.4
Chemical Properties
Boiling Point: NA
Density: NA
storage temp: 2-8°C
Solubility: H2O: soluble30mg/mL, clear
Form: powder
Pka: NA
Color: white to beige
InChI: InChI=1/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/s3
InChIKey: PGZUMBJQJWIWGJ-IFAKAUOZSA-N
SMILES: [C@@H]1(OC(CC)CC)C=C(C[C@H](N)[C@H]1NC(=O)C)C(=O)OCC.OP(O)(O)=O |&1:0,10,12,r|
product description
Here are the specific uses of this compound:
Influenza treatment: Oseltamivir is widely used in the treatment of influenza A and B in adults and children 1 year of age and older. It prevents the replication of the virus in the host cell by inhibiting the neuraminidase activity of the influenza virus, especially for influenza A and B viruses.
Influenza prophylaxis: Oseltamivir is also used for the prevention of influenza A and B in adults and adolescents 13 years of age and older. It reduces the spread of the flu virus and reduces the risk of infection.
Dosage and dosage form: Oseltamivir is available in a comprehensive range of formulations, including granules and capsules, which can be taken orally on an empty stomach or after meals, or with food. The recommended dose for adults and adolescents over 13 years of age is 75 mg twice a day for 5 days; The prophylactic dose is 75 mg once a day for at least 10 days.
Medication for special populations: Oseltamivir is also used in special populations, including pregnant and lactating women, and can be used under the guidance of a doctor.
Global recommendation: Oseltamivir is recommended by the Infectious Diseases Society of America (IDSA) guidelines as one of the first-line treatments for influenza and is recommended by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) as the drug of choice for the prevention and treatment of avian influenza viruses.
Efficacy and safety: Oseltamivir has sufficient evidence-based evidence, and its effectiveness has been clinically verified for more than 20 years, showing strong anti-influenza virus activity against influenza A viruses (such as H1N1, H3N2) and influenza B viruses. It is able to shorten the duration of flu symptoms, reduce the severity of symptoms and the occurrence of complications.